Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Drug Profile

Paclitaxel micelle formulation - Nippon Kayaku/NanoCarrier

Alternative Names: Macromolecular micelle paclitaxel; NK 105; Polymeric micelle paclitaxel

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoCarrier
  • Developer Nippon Kayaku
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 09 Oct 2019 Nippon Kayaku completes enrolment in a phase II clinical trials in Breast cancer (Recurrent, Late-stage disease) in Japan before October 2019 (IV) (JapicCTI-183868)
  • 28 Jun 2019 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Japan (IV)
  • 28 Mar 2018 Phase-II clinical trials in Breast cancer (Recurrent, Late-stage disease) in Japan (IV) (JapicCTI-183868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top